- Home
- AEVA vs INBX Comparison
AEVA vs INBX Comparison
Compare AEVA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEVA
- INBX
- Stock Information
- Founded
- AEVA 2019
- INBX 2010
- Country
- AEVA United States
- INBX United States
- Employees
- AEVA N/A
- INBX N/A
- Industry
- AEVA Auto Parts:O.E.M.
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- AEVA Consumer Discretionary
- INBX Health Care
- Exchange
- AEVA Nasdaq
- INBX Nasdaq
- Market Cap
- AEVA 1.0B
- INBX 178.5M
- IPO Year
- AEVA N/A
- INBX 2020
- Fundamental
- Price
- AEVA $27.62
- INBX $14.67
- Analyst Decision
- AEVA Buy
- INBX Hold
- Analyst Count
- AEVA 6
- INBX 1
- Target Price
- AEVA $16.20
- INBX N/A
- AVG Volume (30 Days)
- AEVA 2.8M
- INBX 82.4K
- Earning Date
- AEVA 08-06-2025
- INBX 08-12-2025
- Dividend Yield
- AEVA N/A
- INBX N/A
- EPS Growth
- AEVA N/A
- INBX N/A
- EPS
- AEVA N/A
- INBX 111.58
- Revenue
- AEVA $10,326,000.00
- INBX $200,000.00
- Revenue This Year
- AEVA $94.59
- INBX N/A
- Revenue Next Year
- AEVA $165.22
- INBX N/A
- P/E Ratio
- AEVA N/A
- INBX $0.13
- Revenue Growth
- AEVA 95.90
- INBX N/A
- 52 Week Low
- AEVA $2.20
- INBX $10.80
- 52 Week High
- AEVA $38.80
- INBX $17.79
- Technical
- Relative Strength Index (RSI)
- AEVA 62.98
- INBX 56.33
- Support Level
- AEVA $23.28
- INBX $14.34
- Resistance Level
- AEVA $38.80
- INBX $15.25
- Average True Range (ATR)
- AEVA 3.15
- INBX 0.82
- MACD
- AEVA 0.61
- INBX -0.09
- Stochastic Oscillator
- AEVA 56.36
- INBX 39.06
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.